Acute Hepatic Injury Associated with Varenicline in a Patient with Underlying Liver Disease
- 28 July 2009
- journal article
- case report
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 43 (9), 1539-1543
- https://doi.org/10.1345/aph.1m131
Abstract
Objective: To report a case of acute hepatic injury associated with varenicline. Case Summary: A 53-year-old white male with underlying alcoholic liver disease and history of hepatitis C virus infection experienced elevated aminotransferase and alkaline phosphatase levels consistent with acute hepatic injury after initiation of varenicline for smoking cessation. The hepatic injury manifested 4 weeks after initiation of varenicline therapy at 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and then 1 mg twice daily. Following discontinuation of varenicline, the patient's aminotransferase levels continued to rise for 2 days before steadily decreasing and returning to baseline levels in approximately 4 months. Alkaline phosphatase continued to rise for 8 days after discontinuation of varenicline before returning to baseline within 1 month. Rechallenge was not attempted. Discussion: Varenicline is a novel, first-line agent for smoking cessation. The presentation of this patient is most consistent with an acute hepatic injury related to drug toxicity. The pattern of the patient's elevated hepatic enzyme levels is not consistent with his underlying alcoholic liver disease or hepatitis C. Using the Naranjo probability scale, as well as the Counsel for International Organizations of Medical Science/Roussel Uclaf Causality Assessment Method algorithm for drug-induced liver toxicity, we determined that varenicline was the probable cause of the acute hepatic injury. Varenicline was a possible cause of the acute hepatic injury using the algorithm for drug-induced liver toxicity developed by Maria and Victorino. To our knowledge, this is the first report of acute hepatic injury associated with varenicline. Conclusions: While the benefits of smoking cessation are likely greater than the risk of hepatic injury, clinicians should be cognizant of this reaction associated with varenicline.Keywords
This publication has 18 references indexed in Scilit:
- ASHP Therapeutic Position Statement on the Cessation of Tobacco UseAmerican Journal of Health-System Pharmacy, 2009
- Diagnosis, management, and treatment of hepatitis C: An updateHepatology, 2008
- Review article: the use of potentially hepatotoxic drugs in patients with liver diseaseAlimentary Pharmacology & Therapeutics, 2008
- Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- Mechanisms of drug-induced liver injuryThe AAPS Journal, 2006
- Drug-Induced HepatotoxicityNew England Journal of Medicine, 2003
- Alcoholic liver disease: proposed recommendations for the American College of GastroenterologyAmerican Journal Of Gastroenterology, 1998
- Development and validation of a clinical scale for the diagnosis of drug-induced hepatitisHepatology, 1997
- Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuriesJournal of Clinical Epidemiology, 1993
- A method for estimating the probability of adverse drug reactionsCancer Cell, 1981